2020 CPIP-L Case 12: Immunology – Biotin Interference in Immunoassay: A Potential Cause of Diagnostic Error - CPIP1212W.2020
Untitled Document


This activity will help pathologists become familiar with the biotin interference issue and provide approaches to minimize reporting of erroneous results.

Credit Type: CME
Duration: 1 hour 15 minutes
Launch Date: December 21, 2020
Expiration Date: December 20, 2023 12:00 AM (ET)
Pricing: Junior Member Fee: $10.00
MOC Category: Medical Knowledge, Patient Care

Registration Information
THIS ACTIVITY REQUIRES CREDIT CARD PAYMENT. If you ordered this product in advance, click Learning Search to locate the activity.

To enroll in the series with one easy payment, or to enroll multiple participants from the same institution, call 800-323-4040 option 1. This option is only available until December 31, 2020, after this date this activity is only accessible by an online credit card payment.

Description
Biotin (vitamin B7) is widely used in amounts far above the recommended amount as a supplement to improve skin and hair appearance, and as a treatment for certain disorders. Because the attachment of biotin to streptavidin is often used as part of the detection system in immunoassays, large amounts of biotin in serum samples may result in erroneous results that can vary by manufacturer and assay. This activity will cover patterns of biotin interference and steps laboratories can take to minimize the effects of this interference.

This clinical pathology activity is intended for pathologists.

NOTE: This CPIP activity is adapted from the Surveys Proficiency Testing Program’s General Chemistry (C-C 2019) educational activity, “Biotin Interference in Routine Clinical Immunoassays,” and contains some verbatim content from that activity.

Objectives
After completing this assessment activity, you should be able to:

  1. Describe the usage, dosage, and pharmacokinetics of biotin.
  2. Recognize the impact of biotin on immunoassays.
  3. Explain the consequences of biotin interference from a clinical standpoint.
  4. Identify the possible approaches to prevent consequences of biotin interference.

Related Link
Clinical Pathology Improvement Program

CME Information
Accreditation: The College of American Pathologists (CAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Category 1: The College of American Pathologists designates this internet enduring material educational activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Passing Requirements
You must answer the assessment questions and complete the evaluation to claim credit and print your certificate.

Payment Information
To pay with a check, print a copy of this page and send it with your check to the address below. You will be notified when your payment has been processed and you have been registered into the activity.

College of American Pathologists
Education Division
325 Waukegan Road
Northfield, IL 60093-2750

Refund Policy
Refunds will be handled on an exception basis. Please submit your request to the CAP in writing via email at education@cap.org or fax at 847-832-8006.

Technical Requirements
Pop-up blockers must be turned off.

CAP Learning has recognized that some Veteran’s Administration, US Government, and military participants may have difficulty accessing the online assessment portion of this activity. If you experience difficulty or have any questions, please contact a representative of the CAP Learning Division at 800-323-4040 option 1 or education@cap.org.

Availability
This activity and evaluation are available December 21, 2020, and expire December 20, 2023, at 12:00 AM (ET). You MUST claim credit by this date and time.

CC: CPIP1212W.2020






Non-Member Price:     
 
Member Price:    

2020 CPIP-L Case 12: Immunology – Biotin Interference in Immunoassay: A Potential Cause of Diagnostic Error